Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Sequential sector conjunctival epitheliectomy as a successful treatment for corneal conjunctivalization secondary to haemorrhagic conjunctivitis sequel

Poster Details

First Author: N.Sabater-Cruz SPAIN

Co Author(s):    J. Mauricio   J. Costa-Vila                 

Abstract Details

Purpose:

Evaluate the effectiveness of Sequential Sector Conjunctival Epitheliectomy for corneal conjunctivalization due to limbal stem cell deficiency secondary to haemorrhagic conjunctivitis sequel

Setting:

Admira Vision - Instituto Oftalmologico Integral

Methods:

A 61-year-old male complained of blurred right vision for 2 months. He had a haemorrhagic conjunctivis 22 years ago diagnosed and treated in his country. Exploration showed: best corrected visual acuity of 0.4 in his right eye and 1.0 in his left eye, right pseudoptosis due to superior symblepharon, intraocular pressure of 14 and 16 mmHg respectively, right corneal hypoaesthesia and right central epithelial defect of 3x4mm with irregular epithelial surface surrounding. Left eye and fundus examination were normal

Results:

After a week with intense ocular lubrication, the defect was closed but epithelial irregularities due to corneal conjunctivalization were more evident, especially on the top part of the cornea and visual axis. Limbal Stem Cell Deficiency was present on the superior limbus and limbus of VI to VII clock hours. 3 sessions of Sequential Sector Conjuntival Epitheliectomy were performed once weekly. Patient noted gradual improvement after each session. One week after last treatment visual acuity was 1.0 in his right eye. In his last follow up 3 months after last treatment, vision remained unchanged

Conclusions:

Sequential Sector Conjunctival Epitheliectomy proved to be beneficial, inexpensive and straightforward treatment of this sequel of haemorrhagic conjunctivitis

Financial Disclosure:

NONE

Back to Poster listing